The company said, "Preliminary, unaudited fourth quarter 2022 worldwide revenue is expected to be approximately $113.8 million, an increase of 11% as reported and 12% on a constant currency basis, compared to $102.8 million in the fourth quarter of 2021. PDN represented approximately $17.3 million in revenue and 16% of worldwide permanent implant procedures in the fourth quarter of 2022. Preliminary, unaudited fourth quarter 2022 U.S. revenue is expected to be approximately $99.8 million, reflecting growth of 13% over $88.4 million in the fourth quarter of 2021. Fourth quarter U.S. trial procedures were up approximately 9% versus prior year. Fourth quarter U.S. PDN trial procedures represented approximately 20% of total U.S. trial volume and grew approximately 15% sequentially over the third quarter of 2022."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
- Nevro downgraded to Underweight from Neutral at Piper Sandler
- Nevro upgraded to Buy from Hold at Canaccord
- Nevro announces presentation of two abstracts for PDN and NSBP
- Wells Fargo downgrades Nevro to Equal Weight, lowers price target to $43
